IRIS
CANTONETTI, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 32.535
EU - Europa 3.088
AS - Asia 3.035
SA - Sud America 479
AF - Africa 38
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 6
Totale 39.193
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 32.356
SG - Singapore 1.512
DE - Germania 842
CN - Cina 715
IT - Italia 429
UA - Ucraina 429
BR - Brasile 406
HK - Hong Kong 366
IE - Irlanda 336
GB - Regno Unito 258
RU - Federazione Russa 223
FR - Francia 144
CA - Canada 142
VN - Vietnam 131
KR - Corea 118
FI - Finlandia 112
SE - Svezia 103
PL - Polonia 62
MX - Messico 33
AR - Argentina 30
IN - India 30
AT - Austria 27
BE - Belgio 27
NL - Olanda 27
JP - Giappone 25
BD - Bangladesh 22
ID - Indonesia 19
ES - Italia 16
ZA - Sudafrica 16
CZ - Repubblica Ceca 14
EC - Ecuador 14
IQ - Iraq 14
EU - Europa 10
IL - Israele 9
RO - Romania 9
TR - Turchia 9
UZ - Uzbekistan 9
CH - Svizzera 8
CO - Colombia 7
PH - Filippine 7
PK - Pakistan 6
VE - Venezuela 6
AU - Australia 5
MA - Marocco 5
SA - Arabia Saudita 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
CL - Cile 4
EG - Egitto 4
KG - Kirghizistan 4
PE - Perù 4
TH - Thailandia 4
AZ - Azerbaigian 3
BG - Bulgaria 3
KE - Kenya 3
LT - Lituania 3
NO - Norvegia 3
PY - Paraguay 3
TN - Tunisia 3
TW - Taiwan 3
AM - Armenia 2
BB - Barbados 2
BW - Botswana 2
DZ - Algeria 2
GR - Grecia 2
HR - Croazia 2
HU - Ungheria 2
IR - Iran 2
JO - Giordania 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
MK - Macedonia 2
NP - Nepal 2
OM - Oman 2
TG - Togo 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BY - Bielorussia 1
CM - Camerun 1
DK - Danimarca 1
EE - Estonia 1
GE - Georgia 1
GT - Guatemala 1
JM - Giamaica 1
KH - Cambogia 1
MN - Mongolia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RS - Serbia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 39.193
Salva come PNG Salva come JPEG
Città #
Woodbridge 9.266
Wilmington 8.716
Houston 7.676
Ann Arbor 810
Fairfield 769
Singapore 715
Chandler 585
Ashburn 514
Jacksonville 389
Hong Kong 364
Beijing 347
Seattle 339
Dublin 322
New York 306
Cambridge 279
Medford 237
Dearborn 198
Munich 172
Rome 155
Santa Clara 134
Lawrence 114
Mcallen 111
Montréal 110
Los Angeles 102
Zhengzhou 73
Buffalo 70
Mülheim 68
The Dalles 57
Moscow 55
Dallas 52
Menlo Park 52
Ho Chi Minh City 47
Milan 46
São Paulo 43
San Diego 42
Kraków 40
Hefei 34
Shanghai 29
Guangzhou 28
Nuremberg 27
London 25
Hanoi 24
University Park 23
Brooklyn 21
Council Bluffs 21
Norwalk 21
Brussels 20
Mountain View 20
Saint Petersburg 20
Nanjing 19
Chicago 18
Redondo Beach 18
Helsinki 17
Redwood City 16
Tokyo 16
Warsaw 16
Stockholm 15
Atlanta 14
Creede 14
Palo Alto 14
Seoul 14
Falls Church 13
Frankfurt am Main 13
Kunming 13
Phoenix 13
Rio de Janeiro 13
Center 12
San Francisco 12
Toronto 12
Amsterdam 11
Boardman 11
Brno 11
Engelhard 11
Jakarta 11
Nürnberg 11
Orem 11
San Jose 11
Belo Horizonte 10
North Bergen 10
Verona 10
Bologna 9
Boston 9
Columbus 9
Denver 9
Johannesburg 9
Montreal 9
Wuhan 9
Brasília 8
Curitiba 8
Dhaka 8
Naples 8
Turku 8
Vienna 8
Baghdad 7
Hangzhou 7
Hebei 7
Nanchang 7
Quito 7
Salvador 7
Cedarhurst 6
Totale 34.257
Salva come PNG Salva come JPEG
Nome #
Awake thoracoscopic biopsy of anterior mediastinal masses 858
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 529
MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas 497
Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-α (IFN-α) therapy 495
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 474
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: An Italian multicenter randomized trial 460
Recombinant interferon alfa-2b (INTRON A) as post-induction therapy for responding multiple myeloma patients. M84 protocol 460
Treatment of multiple myeloma: A randomized study of three different regimens 459
Il trattamento chirurgico delle rinosinusiti nei pazienti oncoematologici: confronto tra procedure 459
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 458
Non-Hodgkin lymphomas of the central nervous system 453
Ceftriaxone plus amikacin in a single daily dose as empiric antibiotic therapy in granulocytopenic patients 447
Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients 444
Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study 440
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 438
Comprehensive analysis of PTEN status in Sezary syndrome 438
WILL MOLECULAR-BIOLOGY CONTRIBUTE TO REFINE PROGNOSIS AND TO SELECT TREATMENT 435
Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma 434
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. 430
Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma 428
Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas 427
SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION 425
Clinical implication of cytokine and soluble receptor measurements in patients with newly diagnosed aggressive non Hodgkin Lymphomas 424
SEQUENTIAL THERAPY WITH VAPLD AND BORTEZOMIB AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSION BEFORE STEM CELL MOBILIZATION 424
Sezary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusion 423
Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses 423
New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia 421
Peripheral polyneuropathy during treatment with alpha-2 interferon 419
FISH analysis for CML monitoring? 417
Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma? 414
Multiple skin tumors in long-term treatment with hydroxyurea 413
Short term treatment with Escheria coli recombinant human granulocyte- macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease 412
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 412
Mitoxantrone in combination with etoposide and cytarabine for treatment of poor prognosis acute non lymphoid leukemia patients 409
Anaplastic large cell lymphoma Hodgkin's-like: A randomized trial of ABVD versus MACOP-B with and without radiation therapy 403
TREATMENT OF PH-POSITIVE CHRONIC MYELOID-LEUKEMIA WITH ALPHA-INTERFERON (ROFERON-A) - THE ITALIAN COOPERATIVE STUDY-GROUP EXPERIENCE 403
Percutaneus osteoplasty in the treatment of extraspinal painful multiple myeloma lesions. 402
Biological and clinical advances in multiple myeloma: A review 402
Therapy of multiple myeloma. Italian Multiple Myeloma Study Group 400
Menstrual function in patients undergoing chemotherapy for Hodgkin's disease 397
Reduced intensity allogeneic transplantation in primary cutaneous t-cell lymphomas. 397
EVALUATING SURVIVAL AFTER ALLOGENEIC BONE-MARROW TRANSPLANT FOR CHRONIC MYELOID-LEUKEMIA IN CHRONIC PHASE - A COMPARISON OF TRANSPLANT VERSUS NO-TRANSPLANT IN A COHORT OF 258 PATIENTS 1ST SEEN IN ITALY BETWEEN 1984 AND 1986 393
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 391
Psoriasiform sarcoidosis: an unusual variety 390
PROGNOSTIC VALUE OF CEREBROSPINAL FLUID FLOW CYTOMETRY ANALYSIS IN AGGRESSIVE NHL PATIENTS AT HIGH RISK FOR LEPTOMENINGEAL DISEASE: FCM plus MAY PREDICT AN HIGH RISK OF CNS RELAPSE 389
Pegylated, liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphoma: An update 389
Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody 388
Simultaneous occurrence of BCR/ABL1 and RUNX1/RUNX1T1 in a case of therapy-related acute myeloid leukemia 387
CONFIRMATION AND IMPROVEMENT OF SOKAL PROGNOSTIC CLASSIFICATION OF PH+ CHRONIC MYELOID-LEUKEMIA - THE VALUE OF EARLY EVALUATION OF THE COURSE OF THE DISEASE 387
Long term follow up of the italian trial of Interferon-A versus conventional chemotherapy in Chronic Myeloid Leukemia 386
Percutaneous kyphoplasty: indications and technique in the treatment of vertebral fractures from myeloma 385
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial 385
A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias 384
INTERFERON ALFA-2A AS COMPARED WITH CONVENTIONAL CHEMOTHERAPY FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA 382
Percutaneus osteoplasty in the treatment of extraspinal painful multiple myeloma lesions 380
KARYOTYPIC CONVERSION BY INTERFERON AS PREPARATIVE TREATMENT FOR AUTOLOGOUS BMT IN PH POSITIVE CML 379
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 378
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients 378
Bone marrow processing with a gravity sedimentation technique: experience of 13 cases 378
Allogeneic stem cell transplantation for patients with advanced primary cutaneous T-cell lymphoma 377
Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment 376
Monitoring treatment and survbival in Cronic Myeloid Leukemia 374
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia 373
EARLY CHEMOTHERAPY INTENSIFICATION WITH BEACOPP IN HIGH-RISK, INTERIM-PET POSITIVE ADVANCED-STAGE HODGKIN LYMPHOMA, IMPROVES THE OVERALL TREATMENT OUTCOME OF ABVD: A GITIL MULTICENTER CLINICAL STUDY 372
Early responder myeloma: Kinetic studies identify a patient subgroup characterized by very poor prognosis 371
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients 371
Chemotherapy in cutaneous T-cell lymphoma 370
Intermediate stage Hodgkin's disease: Preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy 370
Brain metabolic changes in hodgkin disease patients following diagnosis and during the disease course: An 18F-FDG PET/CT study 369
CLIPI: A new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 366
Disseminated pagetoid reticulosis presenting as cytotoxic CD4/CD8 double negative cutaneous T-cell lymphoma 363
Induction chemotherapy stategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients 361
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 361
Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease 358
Surgical management of rhinosinusitis in onco-hematological patients 355
PROGNOSTIC FACTORS IN CHRONIC MYELOID-LEUKEMIA - RELATIONSHIP WITH INTERFERON AND BONE-MARROW TRANSPLANTATION 348
Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma 348
Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients 347
Reduced-intensity conditioning combined with standard GvHD prophylaxis is tolerable and highly effective for patients with primary cutaneous T-cell lymphomas undergoing allogeneic transplantation in advanced disease stage. 345
Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymph 335
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia 330
Pre-treatment staging of multiple myeloma patients: comparison of whole-body diffusion weighted imaging with whole-body T1-weighted contrast-enhanced imaging. 330
Initial staging of hodgkin's disease: Role of contrast-enhanced 18F FDG PET/CT 324
Early detection of IgH monoclonal rearrangenent in follicular spicules of the nose preceding multiple myeloma diagnosis. Case report and review of the literature 322
[Current aspects of treatment of multiple myeloma] 319
Granulomatous mycosis fungoides responsive to gemcitabine 319
Physician-Patient Relationship: Intervention Opportunities for Multiple Myeloma patients' Needs 317
Molecular expression of bone marrow angiogenic factors, cell-cell adhesion molecules and matrix-metallo-proteinases in plasmacellular disorders: A molecular panel to nvestigate disease progression 265
Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir 215
Recurrent Sweet's syndrome in a patient with multiple myeloma 197
The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma 187
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI) 184
Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations 184
Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients 176
Primary Cutaneous Anaplastic Large Cell Lymphoma of the Oral Cavity Successfully Treated with Brentuximab Vedotin 176
Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance 168
BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant 168
Preliminary results of a counselling programme for fertility preservation in female cancer patients: the experience of the GEMME DORMIENTI network 166
Nephelometric assay of urine free light chains: An alternative and early clinical test for Bence-Jones protein quantification 160
Early chemotherapy intensification with escalated beacopp in patients with advanced-stage hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two abvd cycles: Long-term results of the GITIL/FIL HD 0607 trial 160
Totale 37.409
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.464
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.464
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.607 0 0 0 0 0 670 721 581 143 153 284 55
2021/20221.054 43 107 20 76 30 99 44 42 76 87 55 375
2022/20231.581 167 150 77 160 131 349 180 79 137 10 112 29
2023/2024737 51 20 61 20 38 298 30 31 18 13 25 132
2024/20252.633 92 559 302 143 43 139 210 135 201 238 295 276
2025/20261.887 313 222 516 346 404 86 0 0 0 0 0 0
Totale 39.499